Cannabinoid Derived Pharmaceuticals Industry Review Summit

Memo

Cannabinoid derived pharmaceuticals have faced many challenges in their development. Cannabis prohibition being the original and biggest obstruction to progress. Now the industry has started facing new, more acute challenges like finding suitable patient populations and designing robust trials, working with regulators around the world with varying attitudes towards cannabis, selecting the most pharmacologically appropriate synthetic or phytocannabinoid possible just to name a few. Along with the challenges COVID-19 has created over the past months many of these other challenges have been facing the industry for years. Introducing the first Cannabinoid Derived Pharmaceuticals Industry Review Summit, taking place virtually 19th - 21st January. Attending online will give you access to the same opportunities as a physical attendee through our purpose-built online conference platform. With 20+ hours of content, an interactive pre-conference funding and finance workshop and 5 hours+ of networking with your fellow drug developers, this is the only conference solely focused on the application of cannabinoids for pharmaceutical use in a range of disease indications. Join us as we unite experts from across large pharma, innovative biotechs, academia and solution providers to overcome all the end to end challenges which are holding back therapeutic and commercial success in cannabinoid-based drug development URLs:Tickets: https://go.evvnt.com/584421-2?pid=5569 Brochure: https://go.evvnt.com/584421-3?pid=5569  Date and Time: On Tuesday January 19, 2021 at 9:00 am (ends Thursday January 21, 2021 at 5:00 pm) Prices:Conference + 1 Workshop (Pharma and Biotech): GBP 1748.00,Conference Only (Pharma and Biotech): GBP 1499.00,Conference + 1 Workshop (Service Provider and Vendor): GBP 2148.00,Conference Only (Service Provider and Vendor): GBP 1799.00 Speakers: Simon Benita, Professor and Chairman, Hebrew University of Jerusalem and BioNanoSim Ltd, Eyal Ballan, CTO, Cannabics Pharma, Shimon Lecht, Chief of R and D, CannnRx, Clifton Flack, CEO and Co-Founder, CiiTECH, Brian Murphy, CEO, Emerald Bioscience, Manuel Alfaro De Pra, R and D Coordinator, Entourage Phytolab, Mikael Sodergren, Senior Clinical Lecturer, Imperial College London, Karen Long, Director of Drug Development, InMed Pharmaceuticals, Michael Woudenberg, VP Chemistry Manufacturing and Control, InMed Pharmaceuticals, Jahan Marcu, CSO, International Research Center on Cannabis and Health, Deepak Anand, CEO and Co-Founder, Materia Ventures, Ron Lipsky, Vice President, Business Development and International Relations, MGC Pharmaceuticals, Ltd., Alexandros Makriyannis, Director, Center for Drug Discovery, Northeastern University, Saeid Babaei, CEO, Orpheus Medica, Andrea Leone-Bay, CSO, Receptor Life Sciences, Arnold Lippa, CEO and Co-Founder, RespireRx Pharmaceuticals, Jeff Margolis, CFO, RespireRx Pharmaceuticals, Zohar Koren, CEO, SciCann Therapeutics, Aurelia De Pauw, Vice-President Clinical Programs/ Medical Affairs, Tetra Bio-Pharma, Pavel Gershkovich, Associate Professor of Biopharmaceutics, University of Nottingham, Cris Constantinescu, Professor of Neurology, University of Nottingham, Mauro Maccarrone, Professor and Chair of Biochemistry and Molecular Biology, University of Rome